CHINARES PHARMA

Forecast & Rating11 analysts currently cover CHINARES PHARMA, with about 90.9% giving a positive rating — meaning they expect the stock to rise. The average price target is HK$6.49, about 52.9% upside from the current price of HK$4.25. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 46.2% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study CHINARES PHARMA closely still see room for the stock to rise. Data as of Sep 9, 2026; for reference only and not investment advice.